Cannabinoid

World pioneer in cannabis research, Professor Raphael Mechoulam, has died in Israel at the age of 92. A professor in the Hebrew University School of Pharmacy, Mechoulam began his cannabinoid experiments in the 1960s in Israel. His research team was the first to isolate delta9-THC (THC), the psychoactive component of cannabis, which affects the brain, […]

Michael Sassano, CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. The use of medicinal cannabis across much of the world is still in its infancy. Despite claims of a whole host of benefits, the clinical studies […]

Biomedical startup Cannabotech has partnered with the Californian corporation go NXT LVL in a move which will enable it to manufacture cannabidiol products in California.  Specifically, the agreement will allow Cannabotech’s integrative oncology products to be developed and manufactured at Go NXT LVL’s facilities in accordance with the California Medical Cannabis Regulations. The move has […]

Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its ‘integrative-colon’ products killed over 90% of colon cancer cells. These products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts. The study examined the effect of Cannabotech’s […]

Cronos Group and Ginkgo Bioworks have achieved the first target productivity milestone in their partnership to produce eight cultured cannabinoids.   Using Ginkgo’s platform for organism design and development, Cronos Group has successfully achieved the productivity target for cannabigerolic acid (CBGA), which will support Cronos Group’s planned CBG product launch this fall.   Launched in 2018 with the goal of accessing […]

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW Pharmaceutical’s cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with […]

Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to the potential of certain psychedelic […]

Oxford Cannabinoid Technologies (OCTP) and Evotec have entered into a service agreement to expedite the development of OCTP’s lead compound, OCT461201, a selective cannabinoid receptor Type 2 agonist, towards Phase I clinical trials. This Phase I clinical trial will be aimed at demonstrating the safety and tolerability of the drug product. OCT461201 will enter Evotec’s […]